CN1146423C - 前列腺素产品 - Google Patents

前列腺素产品 Download PDF

Info

Publication number
CN1146423C
CN1146423C CNB998007757A CN99800775A CN1146423C CN 1146423 C CN1146423 C CN 1146423C CN B998007757 A CNB998007757 A CN B998007757A CN 99800775 A CN99800775 A CN 99800775A CN 1146423 C CN1146423 C CN 1146423C
Authority
CN
China
Prior art keywords
cyclohexyl
oxa
chloro
penta
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB998007757A
Other languages
English (en)
Chinese (zh)
Other versions
CN1272063A (zh
Inventor
A��L����
A·L·维纳
S·C·艾尔瑞
3
C·雅伯鲁格
J·A·克里福德
W·E·麦克丘恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22235155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1146423(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of CN1272063A publication Critical patent/CN1272063A/zh
Application granted granted Critical
Publication of CN1146423C publication Critical patent/CN1146423C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CNB998007757A 1998-07-14 1999-06-15 前列腺素产品 Ceased CN1146423C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9278698P 1998-07-14 1998-07-14
US60/092,786 1998-07-14

Publications (2)

Publication Number Publication Date
CN1272063A CN1272063A (zh) 2000-11-01
CN1146423C true CN1146423C (zh) 2004-04-21

Family

ID=22235155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998007757A Ceased CN1146423C (zh) 1998-07-14 1999-06-15 前列腺素产品

Country Status (15)

Country Link
EP (1) EP1011728B1 (https=)
JP (2) JP2002520368A (https=)
KR (1) KR20010021835A (https=)
CN (1) CN1146423C (https=)
AR (1) AR019773A1 (https=)
AT (1) ATE285795T1 (https=)
AU (1) AU743607B2 (https=)
BR (1) BR9906597A (https=)
CA (1) CA2295512C (https=)
DE (1) DE69922916T2 (https=)
ES (1) ES2234270T3 (https=)
PT (1) PT1011728E (https=)
TW (1) TW585769B (https=)
WO (1) WO2000003736A1 (https=)
ZA (1) ZA997794B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4563636B2 (ja) * 1999-09-10 2010-10-13 大正製薬株式会社 プロスタグランジン誘導体
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
WO2002022106A2 (en) * 2000-09-14 2002-03-21 Novartis Ag Stable ophthalmic preparation
EP1486192A4 (en) * 2002-03-18 2010-07-14 Santen Pharmaceutical Co Ltd HIGH-TEMPERATURE-STERILIZABLE INSTILLER
DK1532981T3 (da) * 2002-08-23 2008-01-28 Santen Pharmaceutical Co Ltd Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
WO2006068266A1 (ja) * 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
CN105566192B (zh) * 2006-10-02 2019-01-22 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008096804A1 (ja) 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
EP2193795B1 (en) * 2007-08-29 2014-10-01 Wakamoto Pharmaceutical Co., Ltd. Latanoprost-containing aqueous pharmaceutical composition
WO2009084021A2 (en) * 2007-10-16 2009-07-09 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
WO2011027778A1 (ja) * 2009-09-01 2011-03-10 株式会社アールテック・ウエノ 高眼圧症および緑内障処置のための眼局所投与用組成物
EP2478906A4 (en) 2009-09-17 2013-02-20 Senju Pharma Co AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
EP2627173B2 (en) * 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
ES2953346T3 (es) * 2014-01-10 2023-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto de ácido piridilaminoacético y aceite de ricino polioxietilenado
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
JP5951921B1 (ja) * 2014-12-12 2016-07-13 興和株式会社 組成物
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102568079B1 (ko) * 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
KR102756146B1 (ko) * 2019-06-28 2025-01-17 한미약품 주식회사 저장 안정성이 개선된 라타노프로스트 함유 점안제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785602T2 (de) * 1986-03-13 1993-09-02 Univ Columbia Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
JPS62292719A (ja) * 1986-06-12 1987-12-19 Kaken Pharmaceut Co Ltd 外用澄明水溶性製剤
ZA88963B (en) * 1987-02-27 1989-11-29 Allergan Inc Prostaglandins useful for lowering intraocular pressure
JPH0228112A (ja) * 1988-04-21 1990-01-30 Kaken Pharmaceut Co Ltd 点眼用眼圧調整剤
JP3256997B2 (ja) * 1990-08-30 2002-02-18 千寿製薬株式会社 安定な水性製剤
US5425480A (en) * 1992-12-17 1995-06-20 Ryder International Corporation Dose dispenser having a molded plastic housing with a cavity and a metallic foil wall covering the cavity
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JPH09124484A (ja) * 1995-10-27 1997-05-13 Schering Purau Kk 点眼剤
JPH10101863A (ja) * 1996-09-30 1998-04-21 Nippon Zeon Co Ltd 成形材料
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product

Also Published As

Publication number Publication date
AU743607B2 (en) 2002-01-31
HK1028563A1 (en) 2001-02-23
JP2002520368A (ja) 2002-07-09
ZA997794B (en) 2001-01-02
KR20010021835A (ko) 2001-03-15
ES2234270T3 (es) 2005-06-16
CA2295512C (en) 2009-05-26
DE69922916T2 (de) 2005-06-09
DE69922916D1 (de) 2005-02-03
EP1011728B1 (en) 2004-12-29
BR9906597A (pt) 2000-07-18
ATE285795T1 (de) 2005-01-15
JP2010100652A (ja) 2010-05-06
CA2295512A1 (en) 2000-01-14
EP1011728A1 (en) 2000-06-28
WO2000003736A1 (en) 2000-01-27
TW585769B (en) 2004-05-01
AU4822099A (en) 2000-02-07
CN1272063A (zh) 2000-11-01
PT1011728E (pt) 2005-03-31
AR019773A1 (es) 2002-03-13

Similar Documents

Publication Publication Date Title
CN1146423C (zh) 前列腺素产品
US6235781B1 (en) Prostaglandin product
AU700574B2 (en) Storage-stable prostaglandin compositions
CN1236775C (zh) 用于降低眼高压的组合物和方法
US6011062A (en) Storage-stable prostaglandin compositions
CN1132632C (zh) 缓释药物组合物
CN1268623C (zh) 组合物和使该组合物稳定的方法
CN1313447C (zh) 用于降低眼内压的8－氮杂前列腺素类似物
JP5646331B2 (ja) 新規眼科用組成物
CN1871014A (zh) 含有前列腺素的药物组合物
CN1543348A (zh) 降血压性脂质和噻吗洛尔组合物及其使用的方法
JP2012516187A (ja) 貯蔵安定性プロスタグランジン製品
CN1615880A (zh) 治疗青光眼用并用剂
JP5593345B2 (ja) イソプロピルウノプロストンの分解抑制方法
CN1126545C (zh) 眼科用制剂
JP5252787B2 (ja) 熱的に不安定な薬物の分解抑制方法
DE DK et al. POLYPROPYLENBASIERTE BEHÄLTER FÜR PROSTAGLANDIN-ENTHALTENDE PRODUKTE RECIPIENTS A BASE DE POLYPROPYLENE POUR DES PRODUITS DE PROSTAGLANDINE
HK1028563B (en) Polypropylene containers for prostaglandin products
TW202404569A (zh) 含有賽佩普斯特(Sepetaprost)之眼科用組合物
TW202517277A (zh) 含有賽佩普斯特(Sepetaprost)之點眼液
HK40033075B (en) THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND β BLOCKER
HK1057478A (en) Ophthalmic solution

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ALCON LABS CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: ALCON LAB., INC.

CP01 Change in the name or title of a patent holder

Address after: Texas in the United States

Patentee after: ALCON LABORATORIES, Inc.

Address before: Texas in the United States

Patentee before: Alcon Laboratories, Inc.

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20130609

Decision number of declaring invalidation: 20777

Granted publication date: 20040421